[Treatment of venous thromboembolism in cancer patients].
Okugawa
Toshiharu
T
Department of Obstetrics and Gynecology, Mie University School of Medicine.
Tabata
Tsutomu
T
Yamada
Norikazu
N
D000925:Anticoagulants / Q000627:therapeutic use; D001510:Bed Rest; D001777:Blood Coagulation; D001779:Blood Coagulation Factors / Q000378:metabolism; D005260:Female; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use; D006801:Humans; D008297:Male; D009369:Neoplasms / Q000097:blood / Q000150:complications*; D011379:Prognosis; D011655:Pulmonary Embolism / Q000453:epidemiology / Q000209:etiology* / Q000628:therapy*; D012306:Risk; D017131:Thrombectomy / Q000379:methods; D015912:Thrombolytic Therapy; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use; D014568:Urokinase-Type Plasminogen Activator / Q000627:therapeutic use; D016306:Vena Cava Filters; D020246:Venous Thrombosis / Q000453:epidemiology / Q000209:etiology* / Q000628:therapy*; D014859:Warfarin / Q000627:therapeutic use
D000925:Anticoagulants; D001779:Blood Coagulation Factors; D006495:Heparin, Low-Molecular-Weight; D014859:Warfarin; D010959:Tissue Plasminogen Activator; D014568:Urokinase-Type Plasminogen Activator